These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15662237)

  • 21. Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study.
    Galzerano D; Tammaro P; Cerciello A; Breglio R; Mallardo M; Lama D; Tuccillo B; Capogrosso P
    J Hum Hypertens; 2004 Jan; 18(1):53-9. PubMed ID: 14688811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction of left ventricular mass by antihypertensive treatment does not improve exercise performance in essential hypertension.
    Fagard RH; Lijnen PJ
    J Hypertens; 1997 Mar; 15(3):309-17. PubMed ID: 9468459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
    Dahlof B; Zanchetti A; Diez J; Nicholls MG; Yu CM; Barrios V; Aurup P; Smith RD; Johansson M;
    J Hypertens; 2002 Sep; 20(9):1855-64. PubMed ID: 12195129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study.
    Okin PM; Devereux RB; Jern S; Julius S; Kjeldsen SE; Dahlöf B
    Am J Hypertens; 2001 Aug; 14(8 Pt 1):775-82. PubMed ID: 11497193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial).
    Devereux RB; Dahlof B; Levy D; Pfeffer MA
    Am J Cardiol; 1996 Jul; 78(1):61-5. PubMed ID: 8712120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Left Ventricular Hypertrophy Regression During Antihypertensive Treatment in an Outpatient Clinic (the Campania Salute Network).
    Lønnebakken MT; Izzo R; Mancusi C; Gerdts E; Losi MA; Canciello G; Giugliano G; De Luca N; Trimarco B; de Simone G
    J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28275070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The echocardiographic evolution of left ventricular hypertrophy in treated hypertensive patients. A long-term follow-up].
    Román O; Oyonarte M; Lioi X; Klenner TM
    Rev Esp Cardiol; 1991 Mar; 44(3):153-60. PubMed ID: 1828606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Echocardiography in multicenter clinical trials: experience from the Treatment of Mild Hypertension Study.
    Grandits GA; Liebson PR; Dianzumba S; Prineas RJ
    Control Clin Trials; 1994 Oct; 15(5):395-410. PubMed ID: 8001359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of left ventricular hypertrophy and function during long-term treatment of systemic hypertension with enalapril.
    González-Juanatey JR; Pose Reino A; Román AV; García Acuña JM; Fernández López JA; Cerrato JC
    Am J Cardiol; 1997 Feb; 79(3):373-6. PubMed ID: 9036764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies.
    Schmieder RE; Martus P; Klingbeil A
    JAMA; 1996 May; 275(19):1507-13. PubMed ID: 8622227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study.
    Cicala S; de Simone G; Wachtell K; Gerdts E; Boman K; Nieminen MS; Dahlöf B; Devereux RB
    J Hypertens; 2008 Apr; 26(4):806-12. PubMed ID: 18327092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Left ventricular diastolic dyssynchrony in patients with treatment-naive hypertension and the effects of antihypertensive therapy.
    Kwon BJ; Lee SH; Park CS; Kim DB; Park HJ; Jang SW; Ihm SH; Youn HJ; Seung KB; Kim HY
    J Hypertens; 2015 Feb; 33(2):354-65. PubMed ID: 25333681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996).
    Schmieder RE; Schlaich MP; Klingbeil AU; Martus P
    Nephrol Dial Transplant; 1998 Mar; 13(3):564-9. PubMed ID: 9550628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Various ways of calculating echocardiographic left ventricular mass and their relative prognostic values.
    Muiesan ML; Salvetti M; Monteduro C; Donato F; Rizzoni D; Agabiti-Rosei E
    J Hypertens; 1998 Aug; 16(8):1201-6. PubMed ID: 9794725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arterial hypertension increases left ventricular mass: role of tight blood pressure control.
    Ferrara LA; Vaccaro O; Cardoni O; Mancini M; Zanchetti A
    J Hum Hypertens; 2004 Sep; 18(9):637-42. PubMed ID: 15014537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
    Gerdts E; Wachtell K; Omvik P; Otterstad JE; Oikarinen L; Boman K; Dahlöf B; Devereux RB
    Hypertension; 2007 Feb; 49(2):311-6. PubMed ID: 17178978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
    Devereux RB; Palmieri V; Liu JE; Wachtell K; Bella JN; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Dahlöf B
    J Hypertens; 2002 Jul; 20(7):1445-50. PubMed ID: 12131543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis.
    Pierdomenico SD; Cuccurullo F
    Am J Hypertens; 2010 Aug; 23(8):876-81. PubMed ID: 20414193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accuracy and reproducibility of left ventricular mass measurement by subcostal M-mode echocardiography in hypertensive patients and professional bicyclists.
    Abergel E; Cohen A; Vaur L; Khellaf F; Menard J; Chatellier G
    Am J Cardiol; 1993 Sep; 72(7):620-4. PubMed ID: 8362780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitral E wave deceleration time to peak E velocity ratio and cardiovascular outcome in hypertensive patients during antihypertensive treatment (from the LIFE echo-substudy).
    Chinali M; Aurigemma GP; de Simone G; Mishra RK; Gerdts E; Wachtell K; Boman K; Dahlöf B; Devereux RB
    Am J Cardiol; 2009 Oct; 104(8):1098-104. PubMed ID: 19801032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.